Literature DB >> 17600594

Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2).

Heiner Voigt1, Catherine Merant, Daniel Wienhold, Angelika Braun, Evelyne Hutet, Marie-Frédérique Le Potier, Armin Saalmüller, Eberhard Pfaff, Mathias Büttner.   

Abstract

An increasing demand in livestock animal husbandry for intervention or emergency vaccination strategies requires a rapid onset of protection linked to prevention of infectious agent spread. Using the new recombinant parapoxvirus (PPV) Orf virus (ORFV) as a vaccine expressing the CSFV E2 glycoprotein we demonstrate that a single intra-muscular application confers solid protection. In the prime only concept, multi-site application of the vector vaccine turned out to be superior to single-site application as no pyrexia occurred after virulent CSFV challenge and CSFV neutralizing serum antibodies regularly were detectable before challenge. Vector virus vaccinated swine were able to cope with the lymphocyte and in particular B-cell depression in peripheral blood after challenge showing no clinical signs and no viremia. Early after challenge CSFV-specific IFN gamma production (IFN-gamma) and high neutralizing serum antibody titers clearly differentiated naïve from vaccinated and protected animals. After CSFV challenge neutralizing serum antibodies titers in vector vaccinated swine were significantly higher than those in sera from live attenuated vaccine primed animals. Horizontal challenge virus transmission was prevented under strict sentinel isolation before mingling but not in next-door stables separated by a wooden barrier at the day of challenge. The presence of CSFV-specific pre-challenge serum antibodies although in low titers is a good prognostic parameter for solid protection after ORFV vector vaccination even when a significant CSFV-specific IFN-gamma production was not detectable before challenge. A heterologous prime-boost regimen as a combination of prime with baculovirus-expressed glycoprotein E2 followed by boost with the parapoxvirus vector turned out to be a better immune stimulant than a homologous prime/boost with the modified live CSFV vaccine. A similar beneficial effect became evident when the challenge infection mimicked the booster vaccination after a single PPV vector prime.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600594     DOI: 10.1016/j.vaccine.2007.05.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Immunogenicity in Swine of Orally Administered Recombinant Lactobacillus plantarum Expressing Classical Swine Fever Virus E2 Protein in Conjunction with Thymosin α-1 as an Adjuvant.

Authors:  Yi-Gang Xu; Xue-Ting Guan; Zhong-Mei Liu; Chang-Yong Tian; Li-Chun Cui
Journal:  Appl Environ Microbiol       Date:  2015-03-27       Impact factor: 4.792

2.  Co-expression of the C-terminal domain of Yersinia enterocolitica invasin enhances the efficacy of classical swine-fever-vectored vaccine based on human adenovirus.

Authors:  Helin Li; Pengbo Ning; Zhi Lin; Wulong Liang; Kai Kang; Lei He; Yanming Zhang
Journal:  J Biosci       Date:  2015-03       Impact factor: 1.826

3.  A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein.

Authors:  Ralf Amann; Jörg Rohde; Ulrich Wulle; Douglas Conlee; Rudiger Raue; Olivier Martinon; Hanns-Joachim Rziha
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

Review 4.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

5.  Surface displaying of swine IgG1 Fc enhances baculovirus-vectored vaccine efficacy by facilitating viral complement escape and mammalian cell transduction.

Authors:  Zehui Liu; Yangkun Liu; Yuanyuan Zhang; Yajuan Yang; Jingjing Ren; Xiaoying Zhang; Enqi Du
Journal:  Vet Res       Date:  2017-05-12       Impact factor: 3.683

Review 6.  An overview of live attenuated recombinant pseudorabies viruses for use as novel vaccines.

Authors:  Bo Dong; Dante S Zarlenga; Xiaofeng Ren
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

7.  New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus.

Authors:  Jörg Rohde; Ralf Amann; Hanns-Joachim Rziha
Journal:  PLoS One       Date:  2013-12-20       Impact factor: 3.240

8.  Identification of Toll-like receptor 9 as parapoxvirus ovis-sensing receptor in plasmacytoid dendritic cells.

Authors:  Heiner von Buttlar; Sabine Siegemund; Mathias Büttner; Gottfried Alber
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

9.  Orf Virus-Based Vaccine Vector D1701-V Induces Strong CD8+ T Cell Response against the Transgene but Not against ORFV-Derived Epitopes.

Authors:  Alena Reguzova; Michael Ghosh; Melanie Müller; Hanns-Joachim Rziha; Ralf Amann
Journal:  Vaccines (Basel)       Date:  2020-06-10

10.  Genomic Characterization of Orf Virus Strain D1701-V (Parapoxvirus) and Development of Novel Sites for Multiple Transgene Expression.

Authors:  Hanns-Joachim Rziha; Mathias Büttner; Melanie Müller; Ferdinand Salomon; Alena Reguzova; Dominic Laible; Ralf Amann
Journal:  Viruses       Date:  2019-01-30       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.